Digital Look

Welcome to Digital Look++,
you are not logged in

Renalytix (Reg S) (RENX)

Pharma and Biotech

8.40p

Select chart: EPS | Dividend | Revenue

Period Ending	Period	Revenue ($m)	Pre-tax ($m)	EPS	Dividend
31-Dec-24	Interim	1.25	(8.61)	(5.00)¢	n/a

Year Ending	Revenue ($m)	Pre-tax ($m)	EPS	P/E	PEG	EPS Grth.	Div	Yield
30-Jun-20	n/a	(10.61)	(16.00)¢	n/a	n/a	n/a	n/a	0.0%
30-Jun-21	1.49	(35.79)	(43.00)¢	n/a	n/a	n/a	n/a	0.0%
30-Jun-22	2.97	(49.63)	(78.00)¢	n/a	n/a	n/a	n/a	0.0%
30-Jun-23	3.40	(45.60)	(55.00)p	n/a	n/a	n/a	n/a	0.0%
30-Jun-24	2.29	(33.45)	(31.00)p	n/a	n/a	n/a	n/a	0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Forecasts data is not available for this company.

	5 Yr High	5 Yr Low	5 Yr Avg	Curr / Avg
Latest	n/a	n/a	n/a	0

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

Find out about IFRS and how this affects the financial infomation for all UK companies.